1) Exercise without weight loss is associated with a 10-20% reduction in intra-abdominal fat and waist circumference, while exercise with weight loss leads to greater reductions of 30% in intra-abdominal fat and waist circumference. 2) Rimonabant, a CB1 receptor antagonist, was associated with 4.1-9% placebo-subtracted improvements in weight, waist circumference, HDL cholesterol, and triglycerides in clinical trials. 3) Lifestyle interventions emphasizing diet and exercise can reduce the risk of developing diabetes by 58% compared to 31% for metformin and 7% for placebo.